Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...

Myocarditis III: Medical Management

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...

Myasthenia Gravis ll: Pathophysiology

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...

Disorders of the Skeletal Muscle

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...

Myasthenia Gravis: Diagnostic Tests

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Increased radiographic progression of distal hand osteoarthritis occurring during biologic DMARD monotherapy for concomitant rheumatoid arthritis.

Arthritis research & therapy·2021

Same author

Long-term immunogenicity after yellow fever vaccination in immunosuppressed and healthy individuals.

Vaccine·2020

Same author

Use of vasoactive/vasodilating drugs for systemic sclerosis (SSc)-related digital ulcers (DUs) in expert tertiary centres: results from the analysis of the observational real-life DeSScipher study.

Clinical rheumatology·2019

Same author

Classification, categorization and essential items for digital ulcer evaluation in systemic sclerosis: a DeSScipher/European Scleroderma Trials and Research group (EUSTAR) survey.

Arthritis research & therapy·2019

Same author

There is a need for new systemic sclerosis subset criteria. A content analytic approach.

Scandinavian journal of rheumatology·2017

Same author

The ultrasound compression sign to diagnose temporal giant cell arteritis shows an excellent interobserver agreement.

Clinical and experimental rheumatology·2015

Search research articles

Related Experiment Video

Updated: May 13, 2026

Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach

Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach

Published on: June 5, 2010

[Therapy of myositis].

A D Keck¹, U A Walker

¹Rheumatologische Universitätspoliklinik Basel, Felix Platter-Spital, Burgfelderstr. 101, 4012, Basel, Schweiz.

Zeitschrift Fur Rheumatologie

|March 5, 2013

Summary

Physiotherapy benefits all stages of idiopathic inflammatory myopathies. Treatment for dermatomyositis and polymyositis often starts with glucocorticosteroids, with other agents used for steroid-sparing or escalation.

Area of Science:

Rheumatology
Neurology
Immunology

Context:

Idiopathic inflammatory myopathies encompass dermatomyositis (DM), polymyositis (PM), inclusion body myositis (IBM), and necrotizing autoimmune myopathy (NAM).
Physiotherapy is a cornerstone in managing muscle strength, endurance, and joint mobility across all myositis stages.

Purpose:

To outline current therapeutic strategies for idiopathic inflammatory myopathies.
To detail treatment approaches for specific myositis subtypes, including DM, PM, NAM, and IBM.

Summary:

Initial treatment for DM and PM involves glucocorticosteroids, often supplemented with steroid-sparing agents like azathioprine or methotrexate.
Escalation therapies include intravenous immunoglobulins, tacrolimus, and mycophenolate mofetil (MMF). Cyclophosphamide is reserved for refractory cases.

Related Experiment Videos

Last Updated: May 13, 2026

Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach

Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach

Published on: June 5, 2010

Specific management for NAM involves discontinuing statins and initiating prednisone with immunosuppressants. IBM may benefit from a trial of prednisone, methotrexate, or azathioprine, particularly with elevated CK levels or inflammatory infiltrates.

Impact:

Provides a comprehensive overview of myositis treatment options, aiding clinicians in patient management.
Highlights the importance of individualized therapy based on myositis subtype and disease characteristics.
Informs therapeutic decisions for refractory cases and specific conditions like NAM and IBM.